Produced by 
OCT 11 - 12 2017
Cancer Research & Oncology 2017
23 76 10668

The 5th Annual LabRoots Cancer Research & Oncology Virtual Conference is now On-Demand!  LabRoots invites research professionals, scientists, and clinicians to this premier online conference, making it easier and more cost-effective to learn about recent advances in cancer research. The virtual conference is free to attendees, encouraging worldwide collaboration and connections between colleagues and field experts.


Cancer research has made major advancements in diagnosis, treatments, and the basic understanding of the disease itself. Within the last year, we have seen progress in immunotherapy, treatments involving nanotechnology, advances in targeted and personalized therapeutics and drug development, and a decrease in mortality rates due to a strong focus on learning more about the origination of the disease.

Cancer Research & Oncology 2017 focuses on advancements in prevention, diagnosis and treatment of different cancer types. The world’s thought leaders in cancer research will present their latest discoveries in cancer mechanics and detection as well as clinical aspects such as targeted therapies and novel treatments, all in an international venue conducive to networking.

Our virtual conference allows you to participate in a global setting with no travel or cost to you. You can participate in exactly those parts which you are interested in and be back at your desk or bench in an instant. Virtual events remove time and place restrictions and ensure that everyone who wants to participate can do so. This virtual conference also offers increased reach for the global cancer community with a high degree of interaction through live-streaming video and chat sessions.  Attendees can earn free CME and CE Credits.

Topics for this year's virtual conference included:

  • Computational Oncology
  • Data and Bioinformatics
  • Organ Systems & Oncogenes
    • Breast
    • Urologic Oncology
    • KRas-driven cancers
    • Circulating Tumor Cells
  • Therapeutics and Anti-cancer Drug Discovery
    • Traditional vs novel therapeutics
  • Cancer Diagnostics, Screening and Imaging
    • Personalized diagnostics
  • Industry Landscape
     

Continuing Education

By participating in this virtual event and watching webcast presentations, you can earn Free Continuing Education (PACE) and/or Continuing Medical Education (CME) credits. To earn educational credits, you must view an entire presentation. Following the presentation you must click on the educational credit link provided for that particular speaker and follow the required process. Once you have completed the process, you will receive a certificate for the educational credit.

Use #LRcancer to follow the conversation!
 


Speakers:
  • Senior Investigator, National Cancer Institute, Center for Cancer Research
  • Professor, Endowed Chair in Hyperbaric Medical Research, Emergency Medicine, UC San Diego Health System
  • PhD student, Luxembourg Institute of Health
  • Professor, Arizona State University
  • Senior Scientist, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research (FNLCR)
  • John G Searle Professor of Internal Medicine, Professor and Chair Department of Internal Medicine, Professor of Human Genetics, UMHS Internal Medicine, University of Michigan
  • Co-Founder and CEO, Cellanyx
  • Chief Scientific Officer - Biologics, Envigo
  • Assistant Member, Cell Biology Department, Memorial Sloan Kettering Cancer Center
  • USA Immigration Lawyer, Getson & Schatz, P.C.
  • Associate Professor, Department of Neurosurgery, University of Colorado Denver
  • Archibald Assistant Professor of Cancer Biology, Department of Biological Sciences, Harper Cancer Research Institute, University of Notre Dame
  • Principal Product Application Scientist, NanoString
  • Principal Bioinformaticist, EA Genomics/Q2 Solutions
  • Assistant Professor, Integrated Cancer Genomics Division, Collaborative Sequencing Center Director, Scientific Operations, TGen
  • Professor of Statistics, Biostatistics and Computational Biology, Dana Farber Cancer Institute/Harvard University
  • Chief Science Officer, Pancreatic Cancer Action Network
  • Director, Department of Laboratory Medicine, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center
  • Chief Medical Officer at Castle Biosciences, Baylor College of Medicine
  • Distinguished Scientist and Director, Deeley Research Centre, Co-Director, Cancer Immunotherapy Program, BC Cancer Agency
  • General Manager - Platform Innovation, Abcam Inc.
  • Global Product Manager, QIAGEN
  • Assistant Professor Department of Biomedical Engineering Johns Hopkins University
  • Associate Professor, Department of Family, Population & Preventive Medicine, Stony Brook School of Medicine

Show Resources
Agenda
All times are Pacific Time
  • OCT 11, 2017 06:00 AM PDT
    A Pan-Cancer view of gene expression in Immuno-Oncology with particular applications in ovarian cancer
    Speaker: Wendell Jones, PhD
  • OCT 11, 2017 06:00 AM PDT
    Cancer Chemotherapy and the tools needed to Advance Treatment in a Diverse Racial Population
    Speaker: Jennie Williams, PhD
  • OCT 11, 2017 07:30 AM PDT
    Keynote Presentation: Targeting Molecular Chaperones in Cancer: Lessons Learned from HSP90
    Speaker: Len Neckers, PhD
  • OCT 11, 2017 09:00 AM PDT
    New insights into the role of actin cytoskeleton and autophagy at the immune synapse
    Speaker: Antoun Al Absi
    Sponsored By: MilliporeSigma
  • OCT 11, 2017 09:00 AM PDT
    Personalizing Melanoma Management with Molecular Diagnostics
    Speaker: Federico Monzon, MD
  • OCT 11, 2017 10:30 AM PDT
    Brain Tumor Exosomes in Cancer Immunity: Fat Balls of Immune Confusion
    Speaker: Michael Graner, PhD
  • OCT 11, 2017 10:30 AM PDT
    Characterization and application of the triple immunodeficient R2G2 (Rag2/Il2rg double knockout) mouse model
    Speaker: Lee Coney
    Sponsored By: Envigo
  • OCT 11, 2017 12:00 PM PDT
    Examining Cancer with the minION: Methylation and Structural Variation
    Speaker: Winston Timp, PhD
  • OCT 11, 2017 12:00 PM PDT
    Immunotherapy: A revolution in cancer treatment
    Speaker: Brad Nelson, PhD
  • OCT 11, 2017 01:30 PM PDT
    Pancreatic Cancer: Challenges and Solutions
    Speaker: Lynn Matrisian, PhD, MBA
  • OCT 11, 2017 01:30 PM PDT
    Simultaneous multi-analyte profiling of rare antigen specific T cells with 3D Flow™ Analysis
    Sponsored By: Nanostring Technologies
    Karen Anderson, MD, PhD
    Professor, Arizona State University
    Doug Hinerfeld, PhD
    Principal Product Application Scientist, NanoString
  • OCT 12, 2017 06:00 AM PDT
    Disparities in Colorectal Cancer
    Speaker: John M. Carethers, MD
  • OCT 12, 2017 06:00 AM PDT
    Inference of gene signatures associated with response and resistance to targeted and immunotherapies
    Speaker: Xiaole Shirley Liu, PhD
  • OCT 12, 2017 07:30 AM PDT
    Keynote Presentation: Tumor Re-oxygenation - Basic and Therapeutic Considerations
    Speaker: George Perdrizet, MD, PhD, FACS
  • OCT 12, 2017 09:00 AM PDT
    Circulating Tumor Cells: Clinical Utility, Challenges, and Future Prospects
    Speaker: Qing Meng, PhD
  • OCT 12, 2017 09:00 AM PDT
    Circulating biomarkers - what matters for the isolation of biomarkers from Liquid Biopsy samples
    Speaker: Verena Schramm, PhD
  • OCT 12, 2017 09:00 AM PDT
    Profiling the cell surface of cancer cell lines for biomarker/drug target discovery using MS-based proteomics
    Speaker: Josip Blonder, MD
  • OCT 12, 2017 10:30 AM PDT
    Green Cards for Scientific Researchers: How to Win Your EB-1A/NIW Case
    Speaker: Brian H. Getson, Esq.
    Sponsored By: Getson & Schatz, P.C.
  • OCT 12, 2017 10:30 AM PDT
    Hypersecretion of fibroblast-derived exosomes during chemotherapy promotes pancreatic cancer chemoresistance
    Speaker: Reginald Hill, PhD
  • OCT 12, 2017 12:00 PM PDT
    Comprehensive genomic and transcriptomic analysis of acral melanoma: A path towards therapeutic development
    Speaker: Winnie Liang, PhD
  • OCT 12, 2017 12:00 PM PDT
    Detection of circulating tumour biomarkers using the FirePlex® Technology Platform
    Speaker: Daniel Pregibon, PhD
    Sponsored By: Abcam
  • OCT 12, 2017 12:00 PM PDT
    Live-single-cell phenotypic biomarkers measured from primary biopsy samples: An emerging class of biomarkers toward the development of precision diagnostics and the discovery and development
    Speaker: Ashok Chander, PhD
  • OCT 12, 2017 01:30 PM PDT
    Metabolic Regulation of Cell Fate Decisions
    Speaker: Lydia Finley
    Sponsored By: Agilent Technologies
  • Data and Bioinformatics
  • OCT 11, 2017 06:00 AM PDT
    A Pan-Cancer view of gene expression in Immuno-Oncology with particular applications in ovarian cancer
    Speaker: Wendell Jones, PhD
  • OCT 11, 2017 12:00 PM PDT
    Examining Cancer with the minION: Methylation and Structural Variation
    Speaker: Winston Timp, PhD
  • OCT 12, 2017 12:00 PM PDT
    Comprehensive genomic and transcriptomic analysis of acral melanoma: A path towards therapeutic development
    Speaker: Winnie Liang, PhD
  • Therapeutics and Anti-cancer Drug Discovery
  • OCT 11, 2017 06:00 AM PDT
    Cancer Chemotherapy and the tools needed to Advance Treatment in a Diverse Racial Population
    Speaker: Jennie Williams, PhD
  • OCT 11, 2017 07:30 AM PDT
    Keynote Presentation: Targeting Molecular Chaperones in Cancer: Lessons Learned from HSP90
    Speaker: Len Neckers, PhD
  • OCT 11, 2017 09:00 AM PDT
    New insights into the role of actin cytoskeleton and autophagy at the immune synapse
    Speaker: Antoun Al Absi
    Sponsored By: MilliporeSigma
  • OCT 11, 2017 10:30 AM PDT
    Characterization and application of the triple immunodeficient R2G2 (Rag2/Il2rg double knockout) mouse model
    Speaker: Lee Coney
    Sponsored By: Envigo
  • OCT 11, 2017 12:00 PM PDT
    Immunotherapy: A revolution in cancer treatment
    Speaker: Brad Nelson, PhD
  • OCT 11, 2017 01:30 PM PDT
    Simultaneous multi-analyte profiling of rare antigen specific T cells with 3D Flow™ Analysis
    Sponsored By: Nanostring Technologies
    Karen Anderson, MD, PhD
    Professor, Arizona State University
    Doug Hinerfeld, PhD
    Principal Product Application Scientist, NanoString
  • OCT 12, 2017 06:00 AM PDT
    Inference of gene signatures associated with response and resistance to targeted and immunotherapies
    Speaker: Xiaole Shirley Liu, PhD
  • OCT 12, 2017 07:30 AM PDT
    Keynote Presentation: Tumor Re-oxygenation - Basic and Therapeutic Considerations
    Speaker: George Perdrizet, MD, PhD, FACS
  • OCT 12, 2017 09:00 AM PDT
    Profiling the cell surface of cancer cell lines for biomarker/drug target discovery using MS-based proteomics
    Speaker: Josip Blonder, MD
  • OCT 12, 2017 10:30 AM PDT
    Hypersecretion of fibroblast-derived exosomes during chemotherapy promotes pancreatic cancer chemoresistance
    Speaker: Reginald Hill, PhD
  • OCT 12, 2017 12:00 PM PDT
    Live-single-cell phenotypic biomarkers measured from primary biopsy samples: An emerging class of biomarkers toward the development of precision diagnostics and the discovery and development
    Speaker: Ashok Chander, PhD
  • OCT 12, 2017 01:30 PM PDT
    Metabolic Regulation of Cell Fate Decisions
    Speaker: Lydia Finley
    Sponsored By: Agilent Technologies
  • Cancer Diagnostics, Screening and Imaging
  • OCT 11, 2017 09:00 AM PDT
    Personalizing Melanoma Management with Molecular Diagnostics
    Speaker: Federico Monzon, MD
  • OCT 12, 2017 06:00 AM PDT
    Disparities in Colorectal Cancer
    Speaker: John M. Carethers, MD
  • OCT 12, 2017 09:00 AM PDT
    Circulating biomarkers - what matters for the isolation of biomarkers from Liquid Biopsy samples
    Speaker: Verena Schramm, PhD
  • OCT 12, 2017 12:00 PM PDT
    Detection of circulating tumour biomarkers using the FirePlex® Technology Platform
    Speaker: Daniel Pregibon, PhD
    Sponsored By: Abcam
  • Organ Systems & Oncogens
  • OCT 11, 2017 10:30 AM PDT
    Brain Tumor Exosomes in Cancer Immunity: Fat Balls of Immune Confusion
    Speaker: Michael Graner, PhD
  • OCT 11, 2017 01:30 PM PDT
    Pancreatic Cancer: Challenges and Solutions
    Speaker: Lynn Matrisian, PhD, MBA
  • OCT 12, 2017 09:00 AM PDT
    Circulating Tumor Cells: Clinical Utility, Challenges, and Future Prospects
    Speaker: Qing Meng, PhD
  • Industry Landscape
  • OCT 12, 2017 10:30 AM PDT
    Green Cards for Scientific Researchers: How to Win Your EB-1A/NIW Case
    Speaker: Brian H. Getson, Esq.
    Sponsored By: Getson & Schatz, P.C.
Posters

POSTER SUBMISSION GUIDELINES

Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary, and discuss results with interested colleagues through email. Posters should be submitted as a PowerPoint file. Presentations should incorporate illustrative materials such as tables, graphs, photographs, and large-print text. This content is not peer reviewed. Submission is free.

SUBMIT YOUR ABSTRACT

Enter the following information to this Submission Form:

  • Poster Title
  • Your Name
  • Your Institution
  • Your Email
  • Abstract describing the poster

All submitted abstracts will be reviewed and decisions regarding acceptance will be made as abstracts are received. You will be notified within one week of receipt about acceptance. Further details and registration materials will be provided at that time. You do not have to be present in order to have a poster displayed. Only those abstracts approved by LabRoots may display posters at this event.

If accepted, you will also have the opportunity to record a 3-5 minute summary video for each poster. LabRoots will work with each individual to create these videos. Video links and email contact information will be included on each poster displayed.

Questions? Email Posters@LabRoots.com

LabRoots Policy

Speakers

  • Len Neckers, PhD
    Senior Investigator, National Cancer Institute, Center for Cancer Research
    Biography
      Dr. Neckers received his Ph.D. from the University of Connecticut, completed postdoctoral training at the NIH, and joined the NCI in 1981. He became Chief of the Tumor Cell Biology Section, Medicine Branch, in 1988. An early proponent of translational research, Dr. Neckers pioneered development of oligonucleotide-based therapeutic strategies. Recently, Dr. Neckers has been investigating the role of chaperone proteins in signal transduction. His identification of benzoquinone ansamycins as specific antagonists of the chaperone HSP90 uncovered the importance of this protein for the growth and survival of cancer cells and led directly to the first phase I clinical trial of an HSP90 antagonist as an anticancer agent. Dr. Neckers continues to examine the pivotal role of Hsp90 in cancer cell survival, and participates in the ongoing translational development of Hsp90 inhibitors as novel anti-cancer agents. Dr. Neckers holds several patents and has been the recipient of several NIH Merit and NIH Inventor's Awards.
    • George Perdrizet, MD, PhD, FACS
      Professor, Endowed Chair in Hyperbaric Medical Research, Emergency Medicine, UC San Diego Health System
      Biography
        Dr. Perdrizet holds the Ted and Michele Gurnee Endowed Chair in Hyperbaric Medicine and Professor of Emergency Medicine at UC San Diego. He is board certified in General Surgery and Hyperbaric Medicine and practiced general, transplant, trauma surgery and wound care in Hartford Connecticut for 20 years before recently relocating to Southern California to focus on translational research in hyperbaric medicine. His interests are in understanding the cellular response to stress and how it may be manipulated by HBOT in the setting of acute and chronic tissue hypoxia.
      • Antoun Al Absi
        PhD student, Luxembourg Institute of Health
        Biography
          Antoun Al Absi is a 4th year Phd student at the University of Strasbourg, France and the Luxembourg Institute of Health (LIH), Luxembourg. He hold a degree of Pharmacy from the Faculty of Pharmacy at the Arab International University, Damascus, Syria. In 2010, he joined the University of Strasbourg to obtain a Master's degree on Science of Medicaments, major Pharmacology, and also a University Diploma in clinical research. During his masters, He worked on the innate immune system and especially on Neutrophil Extracellular Traps (NETs) at the Institut de Génétique et de Biologie Moléculaire et Cellulaire in Strasbourg, France. Antoun started his PhD in 2014 at the Laboratory of Experimental Cancer Research, Department of Oncology at the Luxembourg Institute of Health. The objectives of Antoun's thesis is to study the role of breast tumor actin cytoskeleton in the resistance to natural killer (NK) cell-mediated cell lysis. With the use of the imaging flow cytometry, He studied the immune synapse between tumor cells and NK cells and applied various masks and features to characterize 1) actin cytoskeleton modification, 2) lytic granules transfer 3) ligand and receptor accumulation and 4) autophagosome clustering.
        • Karen Anderson, MD, PhD
          Professor, Arizona State University
          Biography
            Dr. Karen Anderson M.D., Ph.D., is a Professor at Arizona State University. She received her M.D. and Ph.D. in Microbiology and Immunology from Duke University. Dr. Anderson is a Registered Physician and a member of the American Association for Cancer Research as well as American Society of Clinical Oncology. Dr. Anderson's laboratory is focused on understanding how the immune response can be used to detect and alter cancer development. The development of effective cancer immunotherapy requires identification of target antigens, and also an understanding of the mechanisms of immune regulation that limit effective immunotherapy. One challenge in tumor immunology is how to measure immune responses across the proteome. Antibodies to tumor antigens can be detected in the blood of cancer patients, and can be used as biomarkers for early cancer detection.
          • Josip Blonder, MD
            Senior Scientist, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research (FNLCR)
            Biography
              Dr. Blonder is the Clinical Proteomics Lead at the Cancer Research Technology Program at Frederick National Laboratory for Cancer Research (FNLCR), operated by Leidos Biomedical Research, Inc. For the National Cancer Institute. In 1978, Dr. Blonder received his M.D. at the Rijeka University School of Medicine, Croatia. In 2000, through Associated Western Universities, Dr. Blonder was awarded a post-doc fellowship in proteomics at the Pacific Northwest National Laboratory (PNNL), Richland, WA (Advisor: Dr. Richard D. Smith). In 2002, Dr. Blonder joined the Laboratory of Proteomics & Analytical Technology, at the FNLCR (formerly NCI-Frederick) where he continues to develop and apply MS-based proteomics to cancer research. Since 2006, he has led the Clinical Proteomics Group, extending his research to in-depth profiling of membrane proteome. In parallel, he worked on the methodology for cancer biomarker and drug target discovery using clinical specimens. His group was the first to optimize the immunodepletion of abundant proteins from tissue homogenates. In 2013, Dr. Blonder joined the Antibody Characterization Laboratory to lead the cell surface project within the Ras Initiative at the FNLCR/NCI focused on discovery of cell surface targets, enriched or unique to cancers driven by mutated RAS that could be targeted by drugs, antibodies, antibody-drug conjugates, or nanoparticles. This effort resulted in the first cell surface proteome map of a model cell line expressing oncogenic KRasG12V. Dr. Blonder brings unique combination of his expertise in clinical proteomics, medicine and systems biology, focusing his research on the development of innovative approaches for cancer biomarker and drug target discovery. He is an editor of the BMC Cancer and a lecturer at the Foundation for Advanced Education in the Sciences at NIH. Dr. Blonder has authored over 60 scientific publications in areas of biological mass spectrometry, clinical proteomics and cancer research.
            • John M. Carethers, MD
              John G Searle Professor of Internal Medicine, Professor and Chair Department of Internal Medicine, Professor of Human Genetics, UMHS Internal Medicine, University of Michigan
            • Ashok Chander, PhD
              Co-Founder and CEO, Cellanyx
              Biography
                As CEO of Cellanyx, Ashok is commercializing a biopsy-on-a-chip platform technology that enables precision diagnostics and personalized therapeutics for prostate and breast cancers. Cellanyx is leveraging the unique capability to rapidly analyze live patient-biopsy-cells on an ex vivo platform powered by microfluidics, phenotypic biomarkers, machine vision, and machine learning. Cellanyx's first-in-class platform is poised to dramatically disrupt the diagnostics and therapeutic tools markets that historically have been limited by static formalin-fixed cells, bulk and noisy genomic analysis, irrelevant cell line cultures and cumbersome animal models. Ashok developed Cellanyx's core technology during an academic career researching topics including multidrug resistance and matrix-biology. A Fellow of Startup Leadership Boston, Ashok combines his background in biophysics with expertise in business on project management, operations, team development, entrepreneurship and raising capital. Passionate about translating basic scientific discoveries into therapeutic gains, and engaged in oncology research since 1996, Ashok is exceptionally motivated to create meaningful value for patients, physicians, payers, and investors. Ashok enjoys collaborating with executives, clinicians, engineers, and scientists to advance our understanding of biological processes, promote discovery, develop clinically actionable technologies, and create sustainable clinical and therapeutic value. Ashok began his scientific training at the National Institutes of Health (NIH). Advised by two Nobel Laureates, Ashok received his S.B. in Biology from MIT and Ph.D. from Columbia University. Raised in Potomac, Maryland, Ashok is a lifelong tennis player and new father, appreciating their respective emphases on preparation, dedication, stamina, and good hands.
              • Lee Coney
                Chief Scientific Officer - Biologics, Envigo
                Biography
                  Lee was recruited by Huntingdon Life Sciences at the end of 2004 to take a leading role in working with customers developing biopharmaceutical products. Lee brought to the role hands-on experience of biopharmaceutical drug development gained in companies such as; Cantab Pharmaceuticals, Xenova and CellFactors. During his time in the biotechnology industry, he was involved in developing therapies including: vaccines, recombinant proteins; monoclonal antibodies; immunomodulatory molecules; viral and non-viral gene delivery systems; and cell-based therapies. He has a well-rounded knowledge of the regulatory environment for biologics and particular expertise in the analysis of protein and viral products. At Envigo, Lee is Chief Scientific Officer - Biologics. He is also a serving committee member on the Monoclonal Antibody Expert Working Group of the National Centre for the 3Rs, The BIA Manufacturing Advisory Committee, the RSC / RPS Joint Pharmaceutical Analysis Group the ABPI Nonclinical and Biological Discovery Expert Network (NaBDEN) committee.
                • Lydia Finley
                  Assistant Member, Cell Biology Department, Memorial Sloan Kettering Cancer Center
                  Biography
                    Lydia Finley is an Assistant Member in the Cell Biology Program at Memorial Sloan Kettering Cancer Center. Dr. Finley received her BS from Yale University and then completed her PhD in the laboratory of Dr. Marcia Haigis at Harvard Medical School. As a postdoctoral fellow in the laboratory of Dr. Craig Thompson at Memorial Sloan Kettering Cancer Center, Dr. Finley identified metabolites that contribute to the regulation of stem cell self-renewal. Her current work investigates the mechanisms that link metabolic pathways to cell fate decisions. She is the recipient of the Jack Sorrell Fellowship of the Damon Runyon Cancer Research Foundation and the Dale F. Frey Award for Breakthrough Scientists.
                  • Brian H. Getson, Esq.
                    USA Immigration Lawyer, Getson & Schatz, P.C.
                    Biography
                      Brian Getson is a graduate of the University of Pennsylvania Law School with 20 years of experience. He is a leading U.S. immigration lawyer who represents scientific researchers in applying for green cards and is the principal of a boutique immigration law firm based in Philadelphia. Mr. Getson has given presentations on "Green Cards for Scientific Researchers" at numerous major scientific conferences, the Wistar Institute, and at Universities. Mr. Getson often provides a money back guarantee to qualified applicants giving clients confidence that they will get results. See his website, researchergreencard.com for more information.
                    • Michael Graner, PhD
                      Associate Professor, Department of Neurosurgery, University of Colorado Denver
                      Biography
                        Graner is an Associate Professor of Neurosurgery at the University of Colorado Denver, Anschutz Medical Campus (which is actually in Aurora, and he is not an actual neurosurgeon). He received his PhD in Biochemistry at the University of Illinois (working on fruit flies, of all things). He post-doc'd at the University of Arizona in Cell and Molecular Biology (more flies), and then as assorted sub-faculty level positions in Pediatric Oncology (a perfectly logical transition). There he actually used his biochem training to develop an autologous form of anti-cancer vaccines (called "CRCL", it's a long story). Later, he worked at the Tisch Brain Tumor Center at Duke University, leading to his position in Neuro-Oncology at Colorado. He has continued to study cancer immunology, in particular as it relates to the biology of tumor extracellular vesicles (aka exosomes and microvesicles). He is the Research Director and Steering Committee Chair of the Neurosurgery Nervous System Biorepository, and is the President-Elect of the Society for Thermal Medicine, and has numerous dogs and cats.
                      • Reginald Hill, PhD
                        Archibald Assistant Professor of Cancer Biology, Department of Biological Sciences, Harper Cancer Research Institute, University of Notre Dame
                        Biography
                          I grew up in Cincinnati, Ohio where I found myself drawn to science even at a young age. I attended Florida A&M University and obtained a B.S. in Biology with a focus in Molecular Biology. During the summers I had opportunities to gain research experience through internships at USUHS, Pfizer, and the Genetics Institute. These experiences increased my desire to learn more about the mechanisms underlying disease progression. I continued my education at UNC-Chapel Hill by obtaining a PhD in Genetics and Molecular Biology in the lab of Terry Van Dyke, where I designed and created a new transgenic mouse model of prostate cancer that demonstrated the important role the microenvironment plays in tumor progression. As a Damon Runyon postdoctoral fellow with Dr. Hong Wu at UCLA, I chose to focus on pancreatic adenocarcinoma (PDAC), an under-researched disease with a high mortality rate, poor prognosis, and few therapeutic options. I developed mouse models to recapitulate the complexities of human PDAC in order to uncover new therapeutic strategies that could be translated to the human disease. My lab utilizes genetic models to address fundamental questions about how cell autonomous (e.g. genetic alteration) and cell non-autonomous (e.g. inflammation) mechanisms affect pancreatic cancer development. My focus is to uncover the central mechanisms through which the microenvironment aids tumor initiation, progression, and therapeutic resistance. A better understanding of these processes will not only help the development of more effective treatments for pancreatic cancer, but can be expanded to applications in a wide range of other diseases.
                        • Doug Hinerfeld, PhD
                          Principal Product Application Scientist, NanoString
                          Biography
                            DOUG HINERFELD, PH.D. is the Principal Product Application Scientist for NanoString 3D Biology™ Technology. In this role at NanoString, he is responsible for the development of novel applications for the 3D Biology portfolio. He received a B.A. in Psychology from The University of Colorado, Boulder and a Ph.D. in Genetics and Molecular Biology from Emory University.
                          • Wendell Jones, PhD
                            Principal Bioinformaticist, EA Genomics/Q2 Solutions
                            Biography
                              Dr. Jones is currently Principal Bioinformaticist and Scientific Advisor at Q2 Solutions | EA Genomics. He conducts collaborative scientific research with clients in multiple areas, especially in oncology and immuno-oncology. His background includes leading the analysis, development and validation of the bioinformatic and computational systems that process complex genomic assays (including next generation sequencing assays) evaluating new and emerging genomic technologies, and developing bioinformatic implementation strategies. He consults with clients and provides thought leadership in industry and public consortiums involved in genomic science and measurement. Dr. Jones was recently elected as President-elect of the new Massive Analysis and Quality Control (MAQC) Society. Dr. Jones has over 15 years of experience in advanced genomic technologies and 20 years of experience in scientific and technology leadership positions, including serving as Vice President of Statistics and Bioinformatics at Expression Analysis, Inc and Chief Science Officer at Reliametrics, a Nortel Networks business unit. He has authored or co-authored over 45 peer-reviewed publications and has presented at numerous scientific meetings and industry conferences and consortium workshops. He also supports student research as a faculty adjunct at UNC Chapel Hill in the School of Medicine.
                            • Winnie Liang, PhD
                              Assistant Professor, Integrated Cancer Genomics Division, Collaborative Sequencing Center Director, Scientific Operations, TGen
                              Biography
                                Dr. Liang is Director of the Collaborative Sequencing Center (CSC), Assistant Professor in the Integrated Cancer Genomics and Neurogenomics Divisions, and Director of Scientific Operations at TGen. In 2010, Dr. Liang led the creation of the CSC, which acts as TGen's primary next-generation sequencing resource through collaborative projects. Since its inception, the CSC has completed over 320 projects and has generated over 120Tb of raw sequencing data for studies encompassing a wide spectrum of diseases including pancreatic cancer, cholangiocarcinoma, cutaneous and acral melanomas, Sézary syndrome, breast cancer, Alzheimer's disease, diffuse large B-cell lymphoma, and breast cancer. The CSC has been involved in numerous studies including the SU2C Genomics-Enabled Medicine for Melanoma trial and an acral melanoma study funded by the Melanoma Research Alliance. It is also involved in a longitudinal Multiple Myeloma Research Foundation (MMRF) study along with clinical sequencing studies. Through projects such as these, Dr. Liang is actively in cancer genomics research and the application of next generation sequencing capabilities to unearth somatic variants associated with disease. She is also the genomics lead on a pediatric diffuse intrinsic pontine glioma (DIPG) precision medicine clinical trial with UCSF and PNOC (Pediatric Neuro-Oncology Consortium). Through the Neurogenomics division, Dr. Liang is actively involved in cell-specific transcriptomic characterizations in Alzheimer's disease in order to understand cell-specific contributions to pathogenesis, as well as tuberous sclerosis research in an effort to investigate the molecular basis for phenotypic variability in patients. Ms. Liang received her Bachelor of Science in Biological Sciences (Computational Biology Option) from Carnegie Mellon University, and her Ph.D. from Arizona State University in Molecular and Cellular Biology.
                              • Xiaole Shirley Liu, PhD
                                Professor of Statistics, Biostatistics and Computational Biology, Dana Farber Cancer Institute/Harvard University
                                Biography
                                  Dr. X. Shirley Liu is Professor of Statistics, Biostatistics and Computational Biology at Harvard University, and Director of the Center of Functional Cancer Epigenetics at Dana-Farber Cancer Institute. Her research focuses on algorithm development and integrative modeling of high throughput genomic data to understand the specificity and function of gene expression regulators in tumour development, progression, drug response and resistance. In computational biology, her laboratory developed widely used algorithms for transcription factor motif finding, ChIP-chip/seq, DNase-seq, and CRISPR screen data analysis. In epigenetics, she and colleagues identified the chromatin signature of embryonic pluripotency, and were the pioneers to use the dynamics of nucleosomes, histone marks, and DNase hypersensitivity to predict driving transcription factors and cis-elements in a biological process.
                                • Lynn Matrisian, PhD, MBA
                                  Chief Science Officer, Pancreatic Cancer Action Network
                                  Biography
                                    Lynn M. Matrisian, PhD, MBA, is Chief Science Officer at the Pancreatic Cancer Action Network, based in Manhattan Beach, CA and Washington DC. She focuses on understanding and impacting the scientific and medical activities within the pancreatic cancer field to advance the organizations goal to double survival from pancreatic cancer by the year 2020. She has oversight of the organization's research activities, including the Grants Program, Clinical Trial Finder, Patient Registry, Know Your Tumor and Early Detection Initiative, and sits on the Executive Committee of the personalized medicine initiative Precision Promise. Dr. Matrisian is formerly Professor and the founding Chair of the Department of Cancer Biology at Vanderbilt University. She received her PhD in molecular biology from the University of Arizona and MBA from Vanderbilt University. She is past President of the American Association of Cancer Research, a Fellow of the AACR Academy, and the recipient of the Paget-Ewing award from the Metastasis Research Society. She served as co-chair of the National Cancer Institute's Translational Research Working Group and Special Assistant to the Director of the NCI. Research in her laboratory revolved around the molecular mechanisms underlying tumor progression and metastasis, with emphasis on the biology of matrix-degrading proteinases.
                                  • Qing Meng, PhD
                                    Director, Department of Laboratory Medicine, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center
                                  • Federico Monzon, MD
                                    Chief Medical Officer at Castle Biosciences, Baylor College of Medicine
                                    Biography
                                      Dr. Monzon is a molecular pathologist with extensive experience translating novel genomic technologies into clinical molecular tests. Most recently, he served as Medical Director of Oncology and Medical Director of Latin America at Invitae Corporation, a provider of genetic diagnostics for hereditary disorders. Previously, Dr. Monzon served in several successive roles at Baylor College of Medicine, including Director of Pathology at its Cancer Genetics Laboratory. Earlier in his career, he led studies at the University of Pittsburgh on prostate and renal cancer genomics as well as the validation of one of the first gene expression clinical assays for the diagnosis of tumors of unknown origin. He earned his M.D. from the Universidad Nacional Autónoma de México, and is board-certified by the American Board of Pathology in anatomic, clinical and molecular genetic pathology. Dr. Monzon is the 2016 President-Elect of the Association for Molecular Pathology.
                                    • Brad Nelson, PhD
                                      Distinguished Scientist and Director, Deeley Research Centre, Co-Director, Cancer Immunotherapy Program, BC Cancer Agency
                                      Biography
                                        Dr. Nelson is a native of Vancouver BC. He received his B.Sc. from the University of British Columbia in 1987 and Ph.D. from the University of California at Berkeley in 1991. He completed postdoctoral training with Dr. Phil Greenberg and held faculty positions at the Fred Hutchinson Cancer Research Center and University of Washington in Seattle. In 2003, he became the founding Director of the BC Cancer Agency's Deeley Research Centre in Victoria BC. He is a Professor of Medical Genetics at the University of British Columbia and a Professor of Biochemistry/Microbiology at the University of Victoria. Dr. Nelson's lab uses genomic and molecular approaches to study the immune response to cancer, with an emphasis on ovarian cancer. As Co-Director of the BCCA's Immunotherapy Program, he is leading a phase I clinical trials program focused on adoptive T cell therapy for gynecological cancers, leukemia, lymphoma, and other malignancies.
                                      • Daniel Pregibon, PhD
                                        General Manager - Platform Innovation, Abcam Inc.
                                        Biography
                                          Dr. Daniel Pregibon is the technical founder of Abcam's Firefly® Platform, serving as Abcam's General Manager of Platform Innovation. Dr. Pregibon received his Ph.D. from MIT's Department of Chemical Engineering under the guidance of Drs. Patrick Doyle (MIT) and Mehmet Toner (Harvard/MGH), where he discovered and co-developed Flow Lithography - the technology at the core of the Firefly® Platform. Prior to joining Abcam, he was the President and Chief Technology Officer at Firefly BioWorks, Inc., a start-up that explored the use of the platform for miRNA biomarker validation.
                                        • Verena Schramm, PhD
                                          Global Product Manager, QIAGEN
                                          Biography
                                            Dr. Verena Schramm is a Global Product Manager for RNA sample extraction and Liquid Biopsy at QIAGEN GmbH, Germany. Before taking over these product responsibility, she was a Global Product Manager for NGS library preparation products at QIAGEN. Verena holds and M.Sc. in Molecular Biology and a PhD in Bioinformatics. During her PhD at EMBL Heidelberg she studied the impact of copy-number variation during the evolution of non-human primates using Next-Generation Sequencing. Before joining QIAGEN, Verena worked as a Sales and Business Development Manager DACH, NL and as a Subject Matter Expert at Sophia Genetics a company focusing on the analysis of clinical NGS data in Diagnostics.
                                          • Winston Timp, PhD
                                            Assistant Professor Department of Biomedical Engineering Johns Hopkins University
                                            Biography
                                              Winston Timp is an assistant professor in Biomedical Engineering at Johns Hopkins University. He earned bachelor degrees in Biochemistry, Chemistry, Physics and Electrical Engineering from the University of Illinois at Urbana. He then earned his a masters and PhD in Electrical Engineering from MIT, working at the Whitehead Institute in Paul Matsudaira's lab, focusing his thesis work on the study of cellular communication in a 3D microenvironment. After receiving his doctorate, he trained as a postdoc at Johns Hopkins in the labs of Andrew Feinberg and Andre Levchenko, studying the epigenetics of cancer. My lab's focus is in the development and application of sequencing technologies to gain a deeper understanding of biology and a more accurate set of clinical tools for human disease. We integrate biophysics, molecular biology and computational biology to create new tools for exploring the epigenome and genome. Leveraging these tools, we then explore interesting questions about fundamental biological concepts using model systems. We apply our newfound knowledge and toolset to clinical samples for diagnosis, surveillance and treatment of human disease. Recent projects range from diagnosis of infectious disease using nanopore sequencing, to developing new tools to characterize the genome and epigenome of cancer, to reading the transcriptome of the hummingbird.
                                            • Jennie Williams, PhD
                                              Associate Professor, Department of Family, Population & Preventive Medicine, Stony Brook School of Medicine
                                              Biography
                                                Dr. Williams is an Associate Professor at Stony Brook University with a primary appointment in the Department of Family, Population, and Preventive Medicine and a secondary appointment in the Department of Medicine. She is Assistant Dean for Student Diversity where she serves as the primary liaison between Stony Brook Medicine and Stony Brook University, acting to encourage diverse undergraduate and graduate students to seek out and succeed in careers in the health sciences. Dr. Williams is also an affiliate faculty member in the Institute for STEM Education where she works with underrepresented community college students who are interested in biomedical careers. Dr. Williams has investigated the use of gene therapy in the prevention of AIDS and done extensive work on the effectiveness of non-steroidal anti-inflammatory drugs (NSAIDS), NO-releasing-NSAIDs (NO-NSAIDS), and other pharmacological agents on stemming the progression of cancer. In this capacity, she is defining the mechanistic role of NF-κB and other transcriptional factors in colon cancer prevention in response to novel chemo-therapeutic/-preventive agents. Currently, she is addressing the underlying genetic/regulatory causes associated with cancer racial health disparity. As such, Dr. Williams' group is assessing the dysregulation of miRNAs and aberrant DNA methylation as factors influencing racial health disparity in the incidence and mortality rates of colorectal cancer. Dr. Williams earned her BS from Savannah State University, an MS from Tuskegee University, and a PhD in molecular biology at Purdue University. She completed a postdoctoral fellowship in infectious diseases at Harvard University and conducted postdoctoral work at the New England Regional Primate Research Center's Department of Immunology and the American Health Foundation. Dr. Williams then joined Harvard University as a research scientist and was later recruited to Stony Brook as a Research Assistant Professor, being promoted to Associate Professor with tenure in 2013.
                                              Sponsored By

                                              For information on becoming a sponsor or exhibitor, please click here.


                                              Continuing Education (CME/CE/CEU) Credits

                                              The speakers below have been approved for CME, CE, or CEU credits. To redeem your credits, locate the presentation you watched and click on the CME/CE/CEU buttons for further direction. For more general information regarding continuing education, the processes to receive credits, and the accreditation bodies, Click here

                                              The presentational method for this activity will be Lecture with an opportunity for real-time question and answer periods for the live activity, and on demand access of the presentation for the enduring material activity. Both the internet live activity and the internet activity enduring material is geared towards Oncologists and Primary Care Clinicians; Open to all Health Care Professionals and Academia. This activity will encompass the following desirable physician attributes:  Patient Care & Procedural Skills, Medical Knowledge, Professionalism, and Practice-Based Learning & Improvement.

                                              Desired Outcomes
                                              At the end of the activity, participants should be able to:

                                              1. Integrate the provided content into practice in ways that are consistent with acknowledged practice guidelines and that improve patient management and outcomes
                                              2. Utilize technologies currently available for use in the clinic and the limitations of these technologies
                                              3. Apply current and established medical science principles and the application of these principles to patient care
                                              4. Practice continuous self-assessment and learning to improve one’s professional and clinical practices, including how to interpret results in ways most useful to the patient
                                              5. Cite the role of precision medicine in cancer research & oncology

                                              This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME®) through the joint providership of CME Consultants and LabRoots. CME Consultants is accredited by the ACCME® to provide continuing medical education for physicians.

                                              CME Consultants designates this internet live activity for a maximum of 5.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

                                              CME Consultants designates this internet activity enduring material for a maximum of 5.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

                                              Enduring Material release date: 10/13/17

                                              Enduring Material Termination date: 4/13/18

                                              In accordance with the Americans with Disability Act (ADA), please contact LabRoots at ce@labroots.com should you require special assistance.


                                              Committee

                                              To download the Program Committee brochure here.


                                              • David Albala, MD

                                                Dr. David M. Albala graduated with a geology degree from Lafayette College in Easton, Pennsylvania. He completed his medical school training at Michigan State University and went on to complete his surgical residency at the Dartmouth-Hitchcock Medical Center. Following this, Dr ...

                                                See more See less
                                              • Antonio Baines, PhD

                                                Dr. Antonio T. Baines is an Associate Professor in the Department of Biology at North Carolina Central University (NCCU) and an adjunct professor in the Department of Pharmacology in the School of Medicine at the University of North Carolina (UNC) Chapel Hill. He earned a ...

                                                See more See less
                                              • Josip Blonder, MD

                                                Dr. Blonder leads the Clinical Proteomics Group at the CRTP/FNL. FNL is a Federally Funded Research and Development Center operated by Leidos Biomedical Research, Inc., for the National Cancer Institute (NCI). In 1978, Dr. Blonder received his M.D. at the Rijeka University ...

                                                See more See less
                                              • Rajan Gupta, MD

                                                Dr. Rajan T. Gupta, MD, is an Assistant Professor of Radiology in the Division of Abdominal Imaging at Duke University Medical Center, as well as the Director of the Abdominal Imaging Fellowship Program and a Faculty physician in the Duke Cancer Institute. Since 2009, he has been ...

                                                See more See less
                                              • Martin Latterich, PhD

                                                The discovery of proteinaceous disease biomarkers and their clinical validation is critically important for the enablement of molecular diagnostics and ultimately, precision medicine. In spite of the importance of biomarkers, research done in the last two decades has yielded ...

                                                See more See less
                                              • Ariel Louwrier PhD

                                                Successful Senior Scientific Business Executive with demonstrated expertise growing markets, revenues, product pipelines and expanding technical organizations into new business opportunities. Educational and business management experience in global markets, with quantified ...

                                                See more See less
                                              • Judd Moul, MD, FACS

                                                Judd W. Moul is James H. Semans, MD Professor of Surgery, Division of Urologic Surgery, and Director of the Duke Prostate Center, Duke Cancer Institute at Duke University Medical Center. Prior to joining Duke, he was Professor of Surgery at the Uniformed Services University of ...

                                                See more See less
                                              • Louise Perkins, PhD

                                                Dr. Perkins joined the Melanoma Research Alliance as Chief Science Officer in 2013 where she is responsible for the development and implementation of the MRA's scientific strategy including its research award program and annual Scientific Retreat. Her interests center on ...

                                                See more See less
                                              • Thomas Polascik, MD

                                                Thomas J. Polascik, M.D. is Professor in the Duke Cancer Institute, the Department of Surgery at the Duke University Medical Center, Durham, NC. Dr. Polascik trained at the Brady Urological Institute, the Johns Hopkins Hospital in Baltimore Maryland. After finishing his residency ...

                                                See more See less
                                              • Fred Russell Kramer, PhD

                                                Fred Russell Kramer is Professor of Microbiology and Molecular Genetics at the New Jersey Medical School, and has been a Principal Investigator at the Public Health Research Institute for the past 25 years. He graduated from the University of Michigan in 1964 and received his ...

                                                See more See less
                                              Help

                                              General LabRoots Questions

                                              For bugs, spam, technical support or questions please call +1-714-463-4673 or email support@labroots.com  
                                              Contact us

                                              Virtual Events and Webinars

                                              Supported Configurations

                                              • Operating System Internet Explorer Firefox Chrome Safari
                                                Vista IE8+ FF10+ Chrome15+
                                                Windows 7 IE8+ FF10+ Chrome15+
                                                Windows 8 IE10 FF10+ Chrome15+
                                                Mac OS X   FF10+ Chrome15+ Safari5.1+
                                              • Cookie settings: session cookies enabled
                                              • Browser configuration must have JavaScript enabled
                                              • Adobe Flash player 10.2 or later

                                              To watch our webinars and virtual events a modern browser such as Chrome, Firefox, Safari, or an updated version of Internet Explorer is required.

                                              Internet Connection

                                              • A minimum of 100Kbps is recommended for audio-only events
                                              • A minimum of 300Kbps is recommended for speaker on-video events

                                              Computer Equipment

                                              • Screen Resolution: Minimum 1024x768
                                              • Video Card: 65,000 colors minimum
                                              • Sound card and speakers (or headphones) for hearing webcast in full format
                                              • Audio Card: 16-bit minimum
                                              • RAM: 512MB of free RAM

                                              Firewall Protocol

                                              • HTTP on port 80 or HTTPS on port 443
                                              • Adobe RTMP on port 1935, 80, or 443 with automatic fall-back to RTMPT (RTMP tunneling) on ports 1935, 80 or 443
                                              • RTMPE (RTMP encrypted) on ports 1935, 80 or 443

                                              Work-At-Home Attendees

                                              • If a corporate VPN is used, confirm that your network traffic is not directed over the company VPN. If it is, please turn off the VPN while attending the virtual event.

                                              For A Seamless Experience

                                              When using a mobile device, FREE Mobile Apps are available:

                                              - For viewing Webinars:

                                              - For viewing Virtual Events

                                              Attendee Guide

                                              • To learn more about how the virtual event works for attendees, download the Attendee Guide (PDF).

                                              Virtual Event and Webinar Support:

                                              Continuing Education (CME/CE) Support

                                              Show Resources
                                              Connect with us